ITRM (Iterum Therapeutics, plc) קצב צמיחת רווח למניה בשנה הנוכחית

Iterum Therapeutics plc (ITRM) minimizes operational risks by outsourcing drug production to external CDMO centers. This annual EPS growth chart provided by GURU.Markets demonstrates a recovery trend, with the metric holding around 0.00. The business model relies on the high margins of proprietary antibiotics, while development is conducted within Western legal frameworks, ensuring full protection from geopolitical sanctions.

Earnings per share dynamics determine the annual growth rate of the business's net yield. This comparison of annual EPS growth measures profit generation efficiency relative to previous periods. While a positive trend confirms capital scaling, sharp peaks often mask the risk of future drawdowns. For Iterum Therapeutics plc (ITRM), this indicator is critical due to its dependence on a single drug. The binary risk of a regulatory decision makes current earnings volatility a determining factor for the company's survival.